ReviewTherapeutic advances in gastroenterology2026
GETECCU: a comprehensive national strategy for excellence in inflammatory bowel disease.
Review in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) was founded in 1990 to improve the clinical care and scientific knowledge of inflammatory bowel disease (IBD) in Spain. From its origins as a clinician-driven collaborative network, GETECCU has developed into a nationally and internationally recognised platform, supporting multicentre research, quality assurance and medical education in IBD. A key achievement has been the development of ENEIDA (Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes Genéticos y Ambientales), a nationwide prospective registry that now includes data from over 100 centres and more than 85,000 patients. ENEIDA has supported a wide range of observational studies and translational projects and has become a cornerstone of Spanish IBD research. Complementing this scientific foundation, the Certification of Units of Excellence programme for certifying IBD units - launched in 2017 - has promoted equity, quality and benchmarking of care. More than 80 units across the country are currently accredited under this system. GETECCU has also prioritised generational renewal through the GETECCU Young Group, which fosters early-career leadership in research and education. In parallel, the society has expanded its international presence, participating in ECCO and Pan-American Crohn's and Colitis Organisation, and co-leading the Five Nations initiative together with peer groups in France, Italy, Israel and Portugal. This article presents an overview of GETECCU's structure, current status and strategic directions. Looking ahead, GETECCU aims to promote research of excellence, continuous education through the translation of scientific knowledge into clinical practice, equitable access to specialised care across regions and the advancement of integrated multidisciplinary care models. GETECCU represents a well-established example of how a national academic group can evolve into a driver of innovation and quality in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.